FDA approves Amgen's interchangeable biosimilar Bkemv

The monoclonal antibody works by binding to the complement C5 protein, preventing the breakdown of red blood cells.

Gilead and Cartography enter deal to develop cancer therapies

Cartography is entitled to receive $20m upfront, followed by additional near-term preclinical milestone payments.

Turn Bio and HanAll to develop therapies for age-related conditions

HanAll's initial investment in Turn Bio in 2022 laid the groundwork for this expanded collaboration.

ASCO 2024: J&J's early radioligand prostate cancer trial reports four patient deaths

Nearly 37% of subjects experienced serious treatment-emergent adverse events, with thrombocytopenia and interstitial lung disease (ILD) being notable events.

Vitestro's robotic blood drawing device meets trial endpoints

The device had a success rate of 95%, with 83% of the participants finding the procedure comparable to or less painful than manual blood draws.

SOTIO Biotech doses first subject in Phase I solid tumour treatment trial

The preclinical data for SOT201 indicated a potential for robust anti-tumour activity and wide clinical applicability.

IGC Pharma enrols two subjects in Alzheimer's therapy trial at Neurostudies

Evaluating the efficacy of IGC-AD1 for treating agitation in Alzheimer’s disease is the trial’s primary objective.

13th Annual Clinical Trials in Oncology East Coast 2024

The upcoming Clinical Trials In Oncology West Coast 2024 will bring together pharma and biotech experts to discuss clinical-stage cancer therapy development.

Register Now